Drug intelligence / Profile preview

TF2 + 90Y-IMP-288

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

A two-step pretargeted radioimmunotherapy combining the bispecific antibody TF2, which binds carcinoembryonic antigen (CEACAM5) and the histamine-succinyl-glycine (HSG) hapten, with the radiolabeled hapten-peptide 90Y-IMP-288 (DOTA-di-HSG). After TF2 targets CEACAM5-expressing tumors and clears from blood, 90Y-IMP-288 is administered and rapidly distributes; its bivalent HSG motif binds TF2 on tumor cells, delivering beta radiation from yttrium-90 to achieve selective tumor irradiation while minimizing normal tissue exposure. Developed clinically in colorectal cancer with imaging/therapeutic sequences using 111In/177Lu analogs and 90Y for therapy.[1][3][7]

Other names: TF2 plus 90Y-IMP-288TF-2 plus 90Y-IMP-288TF 2 plus 90Y-IMP-288TF2 pretargeted 90Y-IMP-288TF-2 pretargeted 90Y-IMP-288TF 2 pretargeted 90Y-IMP-288pretargeted radioimmunotherapy TF2 + 90Y-IMP-288RITCOLON regimen

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)

Beyond the preview

Go deeper on TF2 + 90Y-IMP-288.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TF2 + 90Y-IMP-288.

Explore the full profile